araag2/HINT huggingface dataset:
Clinical trial NCT00070291 (phase 2, status: terminated)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclosporine
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C
Reason stopped: 
    slow accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of angioimmunoblastic T-cell lymphoma (recurrent or refractory) based on
             histologic examination.

          -  At least one objective measurable or evaluable disease parameter.

          -  Have failed at least one type of treatment: chemotherapy, auto-transplant, or steroid
             treatment. Patients may not receive concurrent chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

          -  Adequate renal function as indicated by creatinine <= 1.5 the upper limit of normal
             (ULN).

          -  Adequate liver function as indicated by alkaline phosphatase, Aspartate
             Aminotransferase (AST), and Alanine Aminotransferase (ALT) <= 2x the upper limit of
             normal.

          -  Total bilirubin <= 2x the upper limit of normal.

          -  Age 18 or older.

        Exclusion Criteria:

          -  Prior cyclosporine or Tacrolimus (FK506).

          -  Prior allogeneic transplant.

          -  Evidence of active infection.

          -  Congestive heart failure, kidney failure, liver failure, or other severe
             co-morbidities.

          -  Evidence of active neurological impairment.

          -  Previous history of hypersensitivity to cyclosporine and/or Cremorphor EL
             (polyoxyethylated oil).

          -  History of other malignancies (other than cured carcinomas in situ of the cervix or
             basal cell carcinoma of the skin).

          -  pregnant or breastfeeding women.

          -  Human immunodeficiency virus (HIV) positive.
Clinical trial NCT00550862 (phase 2, status: completed)
Conditions: liver cirrhosis, biliary
ICD codes: Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: int-747, ursodeoxycholic acid (urso), placebo
SMILES: [H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)[C@]([H])(CC)[C@]4([H])C[C@]([H])(O)CC[C@]4(C)[C@@]3([H])CC[C@]12C, [H][C@@]1(CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C)[C@H](C)CCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female age 18 to 70 years.

          -  Stable dose of ursodeoxycholic acid (URSO, UDCA) for at least 6 months prior to
             screening.

          -  Female patients must be postmenopausal, surgically sterile, or prepared to use 2
             methods of contraception with all sexual partners during the study and for 14 days
             after the end of dosing.

          -  Male patients must be prepared to use 2 methods of contraception with all sexual
             partners during the study and for 14 days after the end of the dosing.

          -  Proven or likely PBC, as demonstrated by the patient presenting with at least 2 of the
             following 3 diagnostic factors:

               1. History of increased AP levels for at least 6 months prior to Day 0

               2. Positive AMA titer (>1:40 titer on immunofluorescence or M2 positive by ELISA) or
                  PBC-specific antinuclear antibodies (antinuclear dot and nuclear rim positive)

               3. Liver biopsy consistent with PBC.

          -  Screening AP value between 1.5 and 10 × ULN.

        Exclusion Criteria:

          -  Administration of the following drugs at any time during the 3 months prior to
             screening for the study: colchicine, methotrexate, azathioprine, or systemic
             corticosteroids.

          -  Screening conjugated (direct) bilirubin >2 × ULN.

          -  Screening ALT or AST >5 × ULN.

          -  Screening serum creatinine >1.5 mg/dL (133 mol/L).

          -  History or presence of hepatic decompensation (e.g., variceal bleeds, encephalopathy,
             or poorly controlled ascites).

          -  History or presence of other concomitant liver diseases including hepatitis due to
             hepatitis B or C virus (HCV, HBV) infection, primary sclerosing cholangitis (PSC),
             alcoholic liver disease, definite autoimmune liver disease or biopsy proven
             nonalcoholic steatohepatitis (NASH).

          -  Pregnancy.
Clinical trial NCT01012336 (phase 2, status: completed)
Conditions: chemotherapy-induced nausea and vomiting, ovarian cancer
ICD codes: D61.810, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: aprepitant/ramosetron/dexamethasone
SMILES: [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion criteria

          1. patient is over 18 years

          2. ovarian carcinoma patients who are treated with moderately emetogenic chemotherapy

          3. Karnofsky score > 60

          4. Life expectancy > 4 months

        Exclusion criteria

          1. Any of following conditions (mentally incapacitated or emotional or psychiatric
             disorder, user of any illicit drugs, has an active infection, hypersensitivity to
             ramosetron or aprepitant)

          2. Patients have received a nonapproved drug within last 4 weeks

          3. abnormal laboratory values (AST > 2.5 normal, ALT > 2.5 normal, Bilirubin > 1.5
             normal, Creatinine > 1.5 normal)

          4. Antiemetic drugs within 48 hours of study

          5. Benzodiazepine or opiate within 48 hours

          6. CYP3A4 substrates within 7 days (terfenadine, cisapride, astemizole, pimozide)

          7. CYP3A4 inhibitors (clarithromycin, ketoconazole)

          8. CYP3A4 inducers within 30 days (Barbiturates, rifampicin, carbamazepine)
Clinical trial NCT00057213 (phase 2, status: completed)
Conditions: depressive disorder, major
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: radafaxine
SMILES: C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Major Depressive Disorder (MDD)

          -  Duration of current depressive episode 12 weeks - 24 months

          -  Patients can read and write at a level sufficient to provide a signed consent

          -  If female, patients must be practicing an acceptable method of birth control

        Exclusion Criteria:

          -  Patients have other psychiatric disorders that would affect patient's response to
             treatment

          -  Patients have not responded to two or more adequate courses of antidepressant therapy

          -  Patients cannot be currently abusing illicit drugs or alcohol

          -  Patients are not currently receiving psychotherapy

          -  Patients have received electroconvulsive therapy within 6 months prior to screening

          -  Patients are pregnant or lactating
Clinical trial NCT00153998 (phase 2, status: completed)
Conditions: colorectal cancer, liver metastases
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, Z52.6, K71.8, K71.7, A06.4, C22.0, C22.3, K70.0
Drugs: cetuximab, cetuximab and folfiri, cetuximab and folfox
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with non-resectable, histologically confirmed, synchronous or metachronous
             colorectal liver metastases. Patients with non-resectable metastases are defined as;
             patients with five or more liver metastases; and/or patients with liver metastases
             that are technically non-resectable (local surgeon in cooperation with local
             radiologist will define non-resectability on the basis of remaining functional liver
             tissue, infiltration of all liver veins, infiltration of both liver arteries, both
             portal branches or both bile ducts).

          -  Patients with simultaneous liver metastases are eligible, if the primary tumor has
             been resected at least 1 month prior to chemotherapy.

          -  Karnofsky Performance Status ≥ 80

          -  Informed consent

          -  Adequate bone marrow function, liver and renal function (neutrophils > 1.5 x 10^9/l;
             thrombocytes > 100 x 10^9/l; hemoglobin > 8.0 g/l; bilirubin ≤ 1.5 x upper limit of
             normal [ULN] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT <
             5 x UNL; serum creatinine ≤ 1.5 x UNL)

          -  Age ≥ 18 years

        Exclusion Criteria:

          -  Any evidence of extrahepatic metastases, lymph node metastases and primary tumor
             recurrence

          -  Prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months)

          -  Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy

          -  Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or
             port implantation) ≤ 4 weeks before study entry

          -  Concurrent systemic immune therapy, chemotherapy, or hormone therapy

          -  Investigational agents or participation in clinical trials within 30 days before start
             of the treatment in study

          -  Clinically relevant coronary disease or myocardial infarction within 12 months before
             study entry

          -  Peripheral neuropathy > CTC grade I

          -  Inflammatory bowel disease

          -  Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin
             or pre-invasive carcinoma of the cervix with adequate treatment)

          -  History of severe psychiatric illness

          -  Drug or alcohol abuse

          -  Breast feeding or pregnant women, no effective contraception if risk of conception
             exists (male and female patients)
Clinical trial NCT01450488 (phase 2, status: completed)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: masitinib, masitinib
SMILES: CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(N=C3NC(=CS3)C3=CN=CC=C3)=C(C)C=C2)CC1, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(N=C3NC(=CS3)C3=CN=CC=C3)=C(C)C=C2)CC1
Eligibility criteria:

        Inclusion Criteria:

          1. Patients aged 18 to 60 years, from both sex, and suffering from multiple sclerosis
             either primary progressive or secondary progressive without relapse within 2 years
             before inclusion.

          2. Patients with EDSS score in the range of 2 to 6.5, inclusive

          3. EDSS progression ≥ 1 point within 2 years before inclusion

        Exclusion Criteria:

          1. Disease other than MS responsible for clinical signs and/or MRI lesions

          2. Secondary progressive MS with relapse in the 2 years before inclusion

          3. Treatment with interferon or glatiramer acetate within four weeks prior to treatment
             allocation

          4. Treatment with oral or systemic corticosteroids or ACTH within four weeks prior to
             treatment allocation.

          5. Active current bacterial, viral (including hepatitis B and C, HIV, EBV, CMV, herpes
             zoster, herpes simplex), fungal, mycobacterium, protozoan, or other infection
Clinical trial NCT00165841 (phase 2, status: completed)
Conditions: gastroesophageal reflux disease
ICD codes: K21.9, K21.00, K21.01
Drugs: rabeprazole 20 mg
SMILES: COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3N2)=NC=C1
Eligibility criteria:

        Key Inclusion Criteria:

          1. Male or female patients, 18 to 65 years of age.

          2. If female, not of childbearing potential by reason of surgery, radiation or menopause,
             or of childbearing potential, but using an approved method of contraception since the
             last menstrual period, for example, intrauterine device (IUD), implant, double barrier
             method, or oral contraceptives for at least one cycle. Females of childbearing
             potential must have a negative urine pregnancy test before medication is dispensed.

          3. Patients must report a minimum three-month history of GERD symptoms. GERD symptoms are
             defined as heartburn with or without regurgitation or other associated GERD symptoms.

          4. Patients must have at least 4 days with heartburn per week in each of the 2 weeks
             prior to Screening.

          5. Patients must have no esophagitis, with no proton pump inhibitors (PPIs, prescription
             or OTC), H2 blockers (prescription or OTC) or prokinetics within 14 days, prior to the
             endoscopy.

        Key Exclusion Criteria:

          1. Evidence of significant hepatic, renal, respiratory, endocrine, hematologic,
             neurologic, psychiatric or cardiovascular system abnormalities, unless the Sponsor and
             Investigator agree that the nature and severity of any abnormality is unlikely to
             interfere with the conduct of the study, the interpretation of study results, or the
             health of the patient during the study.

          2. Females must not be pregnant, lactating or have a positive urine eta human chorionic
             gonadotropin (B-hCG) laboratory result.

          3. Patients with a history of allergy or sensitivity to proton pump inhibitors or to
             their inactive ingredients.

          4. Patients with known gastric ulcer, duodenal ulcer, infectious or inflammatory
             conditions of the small or large intestine, malabsorption syndromes, obstruction, a
             history of gastrointestinal malignancy, or prior gastric or intestinal surgery
             (including vagotomy).

          5. Patients who have a history of Barrett's esophagus, esophageal stricture, or pyloric
             stenosis.

          6. Patients with a history of endoscopically-proven esophagitis any time in the past.

          7. Patients who have taken proton pump inhibitors (PPIs, prescription or OTC), H2
             blockers (prescription or OTC) or prokinetics within 14 days, prior to Screening
             endoscopy, or any of these medications within 7 days prior to the single-blind placebo
             run-in period.
Clinical trial NCT00559650 (phase 2, status: terminated)
Conditions: congestive heart failure
ICD codes: I50.20, I50.21, I50.22, I50.30, I50.31, I50.32, I50.40
Drugs: placebo, cinaciguat (bay58-2667)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with decompensated chronic congestive heart failure, NYHA functional class
             III-IV, either ischemic or non-ischemic, requiring hospitalization, and with clinical
             indication for parenteral pharmacotherapy and invasive hemodynamic monitoring (i.e
             indwelling Swan-Ganz pulmonary artery catheter) and PCWP >/= 18 mmHg.

          -  Patients must have the clinical diagnosis of CHF made at least 3 month prior to
             enrollment.

          -  Male or female patients, age 18 years or more.

        Exclusion Criteria:

          -  Females of child-bearing potential.

          -  Acute de-novo heart failure.

          -  Acute myocardial infarction and/or myocardial infarction within 30 days.

          -  Valvular heart disease requiring surgical intervention during the course of the study.
Clinical trial NCT01085097 (phase 2, status: completed)
Conditions: lupus nephritis
ICD codes: B26.83, A51.44, N11.8, N11.9, N12
Drugs: laquinimod, mycophenolate mofetil, prednisolone/prednisone, placebo
SMILES: CCN(C(=O)C1=C(O)C2=C(C=CC=C2Cl)N(C)C1=O)C1=CC=CC=C1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Subjects diagnosed with SLE

          2. Kidney biopsy within 12 months prior to baseline with a histological diagnosis of
             proliferative or membranous Lupus Nephritis

          3. Clinically active Lupus Nephritis as evident by urine protein to creatinine ratio

        Exclusion Criteria:

          1. Subjects with severe renal impairment or dialysis

          2. Subjects with a clinically significant or unstable medical or surgical condition

          3. Women who are pregnant or nursing or who intend to be during the study period.

          4. Women of child-bearing potential who do not practice an acceptable method of birth
             control
Clinical trial NCT00026130 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: fluorouracil, gemcitabine hydrochloride
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed pancreatic adenocarcinoma

               -  Non-metastatic disease that is unresectable due to any of the following:

                    -  Tumor greater than 5 cm

                    -  Bulky lymph nodes greater than 2 cm, but within the radiation port

                    -  Vascular involvement or impingement of major vessels

                    -  Involvement of colon, adrenal glands, or kidney

          -  Measurable or evaluable disease

          -  No prior therapy for pancreatic adenocarcinoma

          -  No peritoneal seeding or other evidence of metastatic disease by laparotomy or
             laparoscopy

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  CTC 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  WBC at least 3,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2.0 mg/dL

          -  AST no greater than 3 times upper limit of normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Cardiovascular:

          -  No myocardial infarction within the past 6 months

        Other:

          -  No other uncontrolled serious medical or psychiatric illness that would preclude study
             compliance

          -  No other malignancy within the past 5 years except limited or curatively treated basal
             cell or squamous cell skin cancer or carcinoma in situ of the cervix

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  See Disease Characteristics

        Chemotherapy:

          -  See Disease Characteristics

        Endocrine therapy:

          -  See Disease Characteristics

        Radiotherapy:

          -  No prior abdominal radiotherapy

        Surgery:

          -  At least 2 weeks since prior major surgery
Clinical trial NCT00625183 (phase 2, status: terminated)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: capecitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    withdrawn due to poor/low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed rectal adenocarcinoma that is involving the distal 12 cm of
             the rectum (above the anal verge)

               -  Staged within 8 weeks prior to initiation of study by endoscopic ultrasound OR
                  MRI or CT scan if endorectal ultrasound is non-conclusive or non-tolerable

               -  T3-T4 tumor or evidence of lymph node involvement defined by the presence of at
                  least 1 enlarged peri-rectal lymph node

          -  No evidence of distant or known metastases

        PATIENT CHARACTERISTICS:

          -  ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%

          -  Life expectancy > 1 year

          -  Leukocytes ≥ 3,000/µL

          -  Absolute neutrophil count ≥ 1,500/µL

          -  Platelet count ≥ 100,000/µL

          -  Total bilirubin ≤ upper limit of normal (ULN)

          -  AST/ALT ≤ 2.5 times ULN

          -  Creatinine ≤ ULN OR creatinine clearance ≥ 60 mL/min

          -  Able to receive oral medication

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No other concurrent or previous malignancies unless disease free for > 5 years
             (excluding nonmelanoma skin cancer)

          -  No neuropathy ≥ grade 2

          -  No history of allergic reaction attributed to compounds of similar chemical or
             biologic composition to oxaliplatin, capecitabine, or selenomethionine

          -  No uncontrolled intercurrent illness including, but not limited to, any of the
             following:

               -  Ongoing or active infection

               -  Symptomatic congestive heart failure

               -  Unstable angina pectoris

               -  Cardiac arrhythmia

               -  Psychiatric illness/social situations that would limit compliance with study
                  requirements

        PRIOR CONCURRENT THERAPY:

          -  No prior radiotherapy to the pelvis

          -  No prior chemotherapy

          -  No other concurrent investigational or anticancer agents or therapies

          -  No concurrent vitamin B6 supplementation (except as part of a standard, multivitamin
             supplement)
Clinical trial NCT00208533 (phase 2, status: completed)
Conditions: autism
ICD codes: Z13.41
Drugs: aripiprazole
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of autism (DSM-IV) made by a boarded child and adolescent psychiatrist.

          -  Males and females.

          -  Aged 12 to 18 years.

          -  Clinical judgment that medication treatment for autism is indicated.

        Exclusion Criteria:

          -  Major medical problems including cardiac, liver, endocrine, or renal diseases.

          -  Uncontrolled seizures.

          -  Baseline QTC greater than 425 msec.

          -  Concomitant treatment with psychotropic medication.

          -  History of prior exposure to aripiprazole.
Clinical trial NCT00629239 (phase 2, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: azd4818, placebo
SMILES: CNC(=O)C1=C(OC[C@@H](O)CN2CCC3(CC4=CC(Cl)=CC=C4O3)CC2)C=C(OC(C)(C)C(O)=O)C(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of COPD, with symptoms for more than 1 year

          -  Current or ex-smokers with a smoking history of at least 10 pack-years (1 pack-year=20
             cigarettes/day for 1 year)

          -  Lung function (FEV1) 40 to 80% of the predicted normal value after using a short
             acting bronchodilator

        Exclusion Criteria:

          -  Clinical suspicion of active tuberculosis

          -  Any current clinically significant respiratory tract disorder other than COPD

          -  History of current clinically relevant arrhythmia, heart block, ECG abnormalities, or
             unstable angina